)
Healthcare is messy. Honestly, anyone who has spent ten minutes in a doctor's office knows that. It’s a chaotic swirl of paper files, fax machines, and disparate digital records that don’t talk to each other. Tempus AI was basically born out of that frustration. Back in 2015, Eric Lefkofsky—the guy who co-founded Groupon—found himself sitting in oncology wards while his wife battled breast cancer. He was floored by the lack of data. Doctors were making life-altering decisions based on intuition and limited studies rather than a comprehensive, real-time map of what actually works for a specific patient's genetic makeup.
So he started Tempus. It’s not just a "cancer company" anymore, though that’s where the roots are. They’ve grown into a massive platform that touches cardiology, neuropsychiatry, and radiology.
What is Tempus AI anyway?
At its core, the Tempus AI company overview is a story of data transformation. They operate one of the world’s largest clinical and molecular databases. You've probably heard of "precision medicine," but Tempus is the one actually building the plumbing for it. They take a tumor sample, sequence the DNA and RNA, and then—this is the key—pair that biological info with the patient's actual clinical history.
How they respond to drugs.
What their imaging looks like.
How long they survived.
👉 See also: Why Your Phone Separation Alert Device is Probably Better Than Find My iPhone
By mashing all that together, they create a "multimodal" dataset. It’s not just a list of mutations; it’s a story of a disease in a specific human being. By early 2026, the company has reached a point where its data library is so vast that it’s essentially becoming the "operating system" for oncology.
The business of being smart
It’s easy to think of them as just a lab. That’s wrong. They make money in three distinct ways that feed into each other like a giant flywheel:
- Genomics: They charge for the actual sequencing tests. This is the bread and butter.
- Data & Insights: This is where the real money is hiding. They license de-identified data to pharmaceutical giants like GSK, Pfizer, and AstraZeneca. These companies use the data to figure out why a drug works for some people but not others.
- Applications: They build AI tools, like Tempus One, which is basically a voice-activated assistant for doctors that lives inside the electronic health record.
Why the 2024 IPO was just the beginning
When Tempus went public in June 2024 under the ticker TEM, there was a lot of skepticism. People wondered if an AI healthcare company could actually scale without burning through billions forever. Well, the numbers coming out in early 2026 tell a pretty aggressive growth story. They recently reported a total contract value exceeding $1.1 billion.
Revenue for 2025 hit roughly $1.27 billion. That’s an 80% jump year-over-year. You don’t see those kinds of numbers in traditional diagnostic labs. It's the "AI premium."
The SoftBank Connection
A huge turning point was the joint venture with SoftBank in Japan, known as SB Tempus. This took their Chicago-born tech and exported it to a massive aging population in Asia. It proved that the model wasn't just a U.S.-specific fluke.
Dealing with the "AI Hype" and reality
Lefkofsky is surprisingly blunt about the AI hype cycle. He’s gone on record saying that while everyone is obsessed with ChatGPT, healthcare data is too messy for a general model to just "fix." You can't just point a generic AI at a hospital’s records and expect a cure for cancer.
Tempus spent years doing the "unsexy" work. They had to build pipelines into over 4,500 hospitals. They had to digitize millions of pathology slides. They had to structure notes written by doctors who probably haven't used a keyboard properly in a decade.
Recent Acquisitions
They haven't been shy about buying their way into new sectors. The acquisition of Ambry Genetics was a massive move into hereditary testing. Then they grabbed Paige, a leader in AI-powered digital pathology. They are essentially trying to own every piece of data that could possibly influence a doctor's decision.
The controversy: Who owns your data?
You can't talk about a Tempus AI company overview without mentioning privacy. They deal with the most sensitive information possible. While the data they sell to pharma is de-identified—meaning your name and social security number aren't attached—it still makes some people nervous.
The counter-argument from the company is pretty simple: without this data sharing, we’re stuck in the 1990s. If we don’t look at the data of the million people who came before you, we can’t figure out what will happen to you. It’s a trade-off. Most patients are okay with it if it means a better chance at survival, but the ethical debate isn't going away.
✨ Don't miss: Sergey Brin 60 Hours: Why the Google Founder Thinks You’re Not Working Enough
Looking ahead: What's next for TEM?
Right now, the company is pushing hard into "Care Pathway Intelligence." This is the idea that the AI shouldn't just give a report; it should watch the patient in real-time. If a patient’s lab results look a certain way, the AI pings the doctor: "Hey, this person is actually a perfect match for a clinical trial happening three miles away."
They are also expanding deep into cardiology. Turns out, the same AI patterns that can predict a tumor's growth can sometimes spot a heart condition before a human cardiologist sees it on an EKG.
Actionable insights for the curious
If you’re looking at Tempus from a business or medical perspective, here are a few things to keep an eye on:
- Watch the "Insights" Revenue: The diagnostic tests are great, but the high-margin growth is in the data licensing. If that number keeps growing at 30%+, the company’s valuation stays high.
- EHR Integration is King: The more Tempus is "baked into" systems like Epic or Cerner, the harder it is for a competitor to kick them out.
- Regulatory Hurdles: Keep an eye on the FDA. They’ve been clearing more AI-based diagnostic tools lately, but any shift in the regulatory wind can slow things down.
The goal here isn't just to be a big company. The goal is to make sure that no doctor ever has to say, "I'm not sure why this isn't working." We're moving toward a world where every treatment is a data-backed certainty rather than a best guess. It’s an ambitious, slightly terrifying, and incredibly expensive mission. But for a company that started because of a personal crisis in a Chicago hospital, they’ve managed to turn that grief into a massive technological engine.
📖 Related: Sony Remote for Sound Bar: What Most People Get Wrong
For anyone tracking the intersection of biology and silicon, Tempus is basically the blueprint. They aren't just using AI to write emails; they're using it to rewrite how we survive.
Key Takeaways for 2026
- Follow the Data Flywheel: The more tests Tempus runs, the better their data gets, which makes their AI smarter, which leads to more doctors ordering tests.
- Multimodal is the Standard: DNA sequencing alone is no longer enough; you need the "full picture" (imaging, clinical notes, and RNA) to be competitive in 2026.
- Profitability Path: With positive adjusted EBITDA reported in late 2025, the company is finally proving it can balance massive R&D with a sustainable business model.